Serum uric acid to high-density lipoprotein cholesterol ratio is a predictor for all-cause and cardiovascular disease mortality in patients with diabetes: Evidence from NHANES 2005–2018
Nutrition, Metabolism and Cardiovascular Diseases · 2024
DOI: 10.1016/j.numecd.2024.07.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2024. Verfasst von Ling Ding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The First Hospital of Qiqihar, Qiqihar, Heilongjiang 161005, PR China. Electronic address: 18845146679@163.com. Hauptthemen laut MEDLINE: Nutrition Surveys, Uric Acid, Cardiovascular Diseases, Cholesterol, HDL. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND AND AIMS: The relationship between uric acid to high-density lipoprotein cholesterol ratio (UHR) and mortality in individuals with diabetes remains uncertain. This study aimed to explore the relationship between serum UHR and all-cause and cardiovascular disease (CVD) mortality in adults with diabetes. METHODS AND RESULTS: A total of 5,665 patients with diabetes were enrolled from the 2005-2018 National Health and Nutrition Examination Survey (NHANES). Mortality data were determined through the National Death Index (NDI) until December 31, 2019. The multivariate hazard ratio (HR) and 95% confidence interval (CI) were examined by Cox proportional risk modeling and threshold effects analysis. Stratified analyses were conducted to identify the populations with high-risk mortality. Among the participants with diabetes, 1,088 all-cause mortality, containing 310 CVD mortality occurred. Following adjustment for multivariate, higher UHR was significantly and nonlinearly associated with increased all-cause mortality (HR 1.02, 95% CI 1.02-1.02) and CVD mortality (HR 1.03, 95% CI 1.03-1.03). Furthermore, a U-shaped relationship between UHR and all-cause and CVD mortality, with a plateau at 12.57% for all-cause mortality and 9.86% for CVD mortality. Below the inflection points, a higher UHR was associated with a 4% reduced risk for all-cause mortality. Conversely, exceeding the inflection points, a 4% higher risk for all-cause and a 3% higher risk for CVD mortality associated with elevated UHR. CONCLUSIONS: Nonlinearity of UHR with all-cause and CVD mortality was observed in adults with diabetes in the United States, with thresholds identified at 12.57% for all-cause and 9.86% for CVD mortality respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The First Hospital of Qiqihar, Qiqihar, Heilongjiang 161005, PR China. Electronic address: 18845146679@163.com.
- Department of Laboratory Medicine, The First Hospital of Qiqihar, Qiqihar, Heilongjiang 161005, PR China.
Zitieren
APA
Ding, L., Guo, H., Zhang, C., Jiang, B., Zhang, S., Zhang, J., & Sui, X. (2024). Serum uric acid to high-density lipoprotein cholesterol ratio is a predictor for all-cause and cardiovascular disease mortality in patients with diabetes: Evidence from NHANES 2005–2018. Nutrition, Metabolism and Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2024.07.001
Vancouver
Ding L, Guo H, Zhang C, Jiang B, Zhang S, Zhang J, et al. Serum uric acid to high-density lipoprotein cholesterol ratio is a predictor for all-cause and cardiovascular disease mortality in patients with diabetes: Evidence from NHANES 2005–2018. Nutrition, Metabolism and Cardiovascular Diseases. 2024. doi:10.1016/j.numecd.2024.07.001
BibTeX
@article{Ding2024,
author = {Ding, Ling and Guo, Haipeng and Zhang, Chao and Jiang, Bo and Zhang, Shuo and Zhang, Jian and Sui, Xin},
title = {Serum uric acid to high-density lipoprotein cholesterol ratio is a predictor for all-cause and cardiovascular disease mortality in patients with diabetes: Evidence from NHANES 2005–2018},
journal = {Nutrition, Metabolism and Cardiovascular Diseases},
year = {2024},
doi = {10.1016/j.numecd.2024.07.001}
}
EUVIMED